Axsome Therapeutics AXSM Finance Lease Right Of Use Asset Amortization
Finance Lease Right Of Use Asset Amortization at other companies
Other financials
Where this comes from
Reported directly by Axsome Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:FinanceLeaseRightOfUseAssetAmortization.
The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Axsome Therapeutics's finance lease right of use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Axsome Therapeutics's finance lease right of use asset amortization?
- Axsome Therapeutics (AXSM) reported finance lease right of use asset amortization of $679K in Q1 2026.
- How has Axsome Therapeutics's finance lease right of use asset amortization changed year-over-year?
- Axsome Therapeutics's finance lease right of use asset amortization increased by 64.8% year-over-year, from $412K to $679K.
- What does finance lease right of use asset amortization mean?
- The non-cash cost of using assets held under finance leases.
- How do you interpret finance lease right of use asset amortization?
- Higher values indicate a larger portfolio of finance-leased assets, often used as an alternative to purchasing equipment.
- How does finance lease right of use asset amortization compare across companies?
- Commonly reported by capital-intensive companies that utilize leasing for operational equipment.